Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


SCHEDULE 13D/A 0001104659-19-056493 0000901832 XXXXXXXX LIVE 1 Ordinary Shares, EUR0.05 nominal value per share 12/22/2025 false 0001598599 45781K105 Innate Pharma SA 117 Avenue de Luminy BP 30191 Marseille I0 13009 Hannah Tattersall 44 0 20 3749 5847 Deputy Company Secretary Eastbrook, Shaftesbury Road Cambridge X0 CB2 8BF 0000901832 N AstraZeneca PLC b OO N X0 7825501.00 0.00 7825501.00 0.00 7825501.00 N 8.3 CO (1) Note to Rows 7, 9 and 11: Represents both Ordinary Shares and Ordinary Shares in the form of American Depositary Shares ("ADSs") held directly by MedImmune Limited, a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over all of the Ordinary Shares held by MedImmune Limited, whether held in the form of Ordinary Shares or ADSs. (2) Note to Row 13: Based upon 93,719,323 Ordinary Shares of the Issuer outstanding as of December 31, 2025, as reported in the Issuer's Form 6-K filed with the Securities and Exchange Commission (the "SEC") on January 7, 2026. 0001790714 N MedImmune Limited b OO N X0 7825501.00 0.00 7825501.00 0.00 7825501.00 N 8.3 CO (1) Note to Rows 7, 9 and 11: Represents both Ordinary Shares and Ordinary Shares in the form of ADSs held directly by MedImmune Limited, a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over all of the Ordinary Shares held by MedImmune Limited, whether held in the form of Ordinary Shares or ADSs. (2) Note to Row 13: Based upon 93,719,323 Ordinary Shares of the Issuer outstanding as of December 31, 2025, as reported in the Issuer's Form 6-K filed with the SEC on January 7, 2026. Ordinary Shares, EUR0.05 nominal value per share Innate Pharma SA 117 Avenue de Luminy BP 30191 Marseille I0 13009 This Amendment No. 1 to the statement on Schedule 13D with respect to the Ordinary Shares, nominal value EUR0.05 per share, of Innate Pharma S.A., filed by the Reporting Persons on October 25, 2019 (such statement, as amended herein the "Schedule 13D"), amends the Schedule 13D as set forth herein. Except as specifically amended by this Amendment No. 1, items in the Schedule 13D remain unchanged. The current directors and executive officers of the Reporting Persons are set forth on Schedule I attached hereto. AstraZeneca PLC: 7,825,501 Ordinary Shares (including 1,565,001 Ordinary Shares represented by ADSs). Represents both Ordinary Shares and Ordinary Shares in the form of ADSs held directly by MedImmune Limited, a wholly-owned subsidiary of AstraZeneca PLC. Percent of class: 8.3%. MedImmune Limited: 7,825,501 Ordinary Shares (including 1,565,001 Ordinary Shares represented by ADSs). Percent of class: 8.3%. AstraZeneca PLC and MedImmune Limited may each be deemed to have sole voting and dispositive power over all of the Ordinary Shares held by MedImmune Limited, whether held in the form of Ordinary Shares or ADSs. Percentage ownership calculated based upon 93,719,323 Ordinary Shares of the Issuer outstanding as of December 31, 2025, as reported in the Issuer's Form 6-K filed with the SEC on January 7, 2026. See the information contained in Item 5(a), which is incorporated herein by reference. Neither the Reporting Persons nor any of the individuals listed on Schedule I have effected any transactions in the Ordinary Shares, including Ordinary Shares represented by ADSs during the past 60 days. AstraZeneca PLC /s/ Matthew Bowden Matthew Bowden / Company Secretary 02/06/2026 MedImmune Limited /s/ Matthew Bowden Matthew Bowden / Director 02/06/2026